Raredr

Myasthenia Gravis Trial Shows Encouraging Results

RDR Staff
Published Online: Wednesday, Mar 15, 2017
Some positive news for Myasthenia Gravis (MG) patients. Catalyst Pharmaceuticals has reported that their clinical trial testing Firdapse (amifampridine phosphate) in MG patients with anti-MuSK antibodies (MuSK-MG) met its primary endpoint.

About the trial

The trial was a randomized, double blind, placebo-controlled, single site, outpatient study assessing Firdapse in patients with MuSK-MG, a rare sub-population of MG patients.
 
Seven patients were then randomized into one of two crossover treatment groups which consisted of three, one-week treatment periods. 
 
The primary efficacy endpoint was change from baseline in total Quantitative Myasthenia Gravis (QMG) score and total Myasthenia Gravis Activities of Daily Living (MG-ADL) score at the 7th day of each period.

Results

Patients demonstrated change from baseline in both QMG score (P = .0003) and MG-ADL score (P = .0006).
 
The drug was also well tolerated in this population of patients.

About MuSK-MG

Approximately 5–8 % of MG patients test positive for antibodies against muscle-specific tyrosine kinase (MuSK). MuSK is a receptor tyrosine kinase required for the formation and maintenance of the neuromuscular junction. 
 
In MG, antibodies block, alter, or destroy the acetylcholine receptors at the neuromuscular junction. The condition is usually treated with acetylcholinesterase inhibitors that can increase the concentration of acetylcholine at the neuromuscular junction.
 


Latest Articles
Positive initial results from a Phase 1A clinical trial evaluating setmelanotide (RM-492) for the treatment of rare genetic disorders of obesity were reported.
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Dr Gavin Rumbaugh, PhD of Scripps Florida Research Institute was awarded an NIMH-funded grant for the therapeutic development of Syngap1.
Cooper sits down with RDR to talk about A4250, why it’s so important to children with PFIC, and just how Albireo prioritizes treatment for rare diseases.
$vacMongoViewPlus$ $vAR$